Savara Inc.


Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its mission is to develop and commercialize novel, best-in-class medicines to address unmet medical needs in rare respiratory conditions, particularly autoimmune pulmonary alveolar proteinosis (aPAP). The company is advancing its lead product candidate, molgramostim, in Phase 3 development, and is dedicated to improving treatment options for patients with these rare diseases.

Industries

biopharma
biotechnology
pharmaceutical

Nr. of Employees

small (1-50)

Savara Inc.

One Summit Square, 1717 Langhorne Newtown Road, Suite 300, Langhorne, PA 19047


Products

Molgramostim inhalation solution (investigational)

Non-glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) formulated for inhalation and developed as a potential treatment for autoimmune pulmonary alveolar proteinosis; in late-stage clinical development.


Services

Global early access policy and program (case-by-case review) to provide investigational product to eligible patients outside of clinical trials, administered in partnership with a specialist expanded access provider.

Provision of medical information resources, support for investigator-sponsored trials, congress participation, and publication planning to disseminate clinical and scientific data.

Expertise Areas

  • Clinical trial management
  • Inhaled biologic development
  • Rare respiratory disease therapeutics
  • cGMP biologics manufacturing and scale-up
  • Show More (7)

Key Technologies

  • Inhalation drug delivery
  • Recombinant protein biologics
  • cGMP manufacturing
  • Technology transfer and scale-up
  • Show More (5)

News & Updates


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.